The issue is, whilst NUH may have demanded the co-development fee ( and who knows if that is actually true ) , they had to borrow money they did not have to pay a co-development fee, whereas all they had to do was do a short term license agreement with RT, take the royalty fees for a year or two, then do it when they had the cash to themselves to pay for it, without jeopardising the company and shareholders money. Your argument you put forward is fine if the company is in a cash positive situation, but it never has been, nor unlikely ever will be now.
It is hugely telling that the Alango/realtek solution is now ready for the African hearing market, laxi/realtek for india market, rehear/relatek/audeara taiwan, and yet realtek are a strategic partner and cornerstone of nuheara, yet have no deals to date and have fixed and floating charges ? It makes no sense to me, nor many others on here. Not one deal, not one MOU, not once cent has come back in two years from this agreement, and all money in has gone back to realtek , so why would that be? Nothing to do with FDA, as it can go into PSAP or any CE equipment.
(20min delay)